

Panacea Biotec Signs agreement with Laboratorios Clausen S.A

New Delhi: 3rd March 2011: Panacea Biotec Limited, India's 3rd largest biotech company has signed a non-exclusive marketing agreement with Laboratorios Clausen S.A, Uruguay. The agreement will give an access to Laboratorios Clausen S.A to market Panacea Biotec Limited's "Tacrolimus" (Pangraf) in few markets in Europe.

The agreement was signed in the august presence of His Excellency Mr. Danilo Astori, Vice President of the Oriental Republic of Uruguay, who was in India on an official visit to sign economic pact.

In a separate agreement of technology exchange, Panacea Biotec Limited agreed to explore the possibility of technology transfer of its product to Laboratorios Clausen S.A manufacturing facility and for subsequent marketing in Latin American markets. In return Laboratorios Clausen S.A agreed to provide technology of Mycophenolate mofetil (MMF) to Panacea Biotec; where in Panacea Biotec will manufacture and market the products in few key international markets.

Both the companies agreed to explore the possibilities of collaboration on products in development.

On this development, Dr. Rajesh Jain, Joint Managing Director, Panacea Biotec Limited said, "We are more than happy to partner with Laboratorios Clausen S.A. and this agreement will help us to explore new opportunities in the Latin American markets. Panacea Biotec always believe in investing in partnerships that provide human, technical and financial resources to engage and empower the community worldwide and this agreement is another milestone in our journey toward our vision 2020"

Other important delegates from the Oriental Republic of Uruguay were also present at the occasion.

About Panacea Biotec

Panacea Biotec is one of India's leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine producer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology company (ABLE Survey- 2010) and is also amongst the top 50 pharmaceutical companies in India. The product portfolio of the Company includes highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. Panacea Biotec has five dedicated research and development centers.

The company has around 3300 employees including over 300 scientists. The company also has 24 product patents, valid in more than 60 countries worldwide.

For further details please contact:

Subhash Y Mantri
GM - Corporate Communications

Mobile: +91-9871430022

Land Line: +91-11-4167 9000; Fax: +91-11-26940621

Email: subhashmantri@panaceabiotec.com

Website: www.panaceabiotec.com